May 31, 2019 Conference
Treatment for wet AMD underwent a profound shift with the development of anti-vascular endothelial growth factor (anti-VEGF) medicines. However, there has not been a new medicine approved for wet AMD since aflibercept in 2011 and there is still no treatment for dry AMD. This talk will discuss current Phase 3 clinical trials for wet AMD including novel anti-VEGFs, drug delivery systems, anti-ang2 compounds, modified antibodies, and biosimilars. Phase 3 trials for dry AMD will also be presented including complement inhibitors and visual cycle modulators. In addition, there will be a brief summary of recently completed, unsuccessful Phase 3 trials for E10030 (Fovista) and Lampalizumab.